Please login to the form below

Not currently logged in
Email:
Password:

Therapy Area

This page shows the latest Therapy Area news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • MSD’s Keytruda catches up in kidney cancer MSD’s Keytruda catches up in kidney cancer

    Keytruda is continuing to prove its lead in the anti-PD-1/PD-L1 therapy area, with this approval closely following its FDA approval in advanced RCC earlier this year. ... BMS’ anti-PD-1 therapy is only approved for patients with intermediate- and

  • Vertex eyes type 1 diabetes cure with biotech acquisition Vertex eyes type 1 diabetes cure with biotech acquisition

    The company has been a pioneer in the CF therapy area, and  recently filed its landmark triple combination therapy with the FDA. ... If approved, the therapy could transform the treatment of the disease, and could be used to treatup to 90% of all

  • Novartis scores promising phase 3 MS study Novartis scores promising phase 3 MS study

    It seems that Novartis is continuing to stake a claim in the MS therapy area, but will have to battle hard with competitors, including Roche’s blockbuster MS drug ocrevus.

  • Tecentriq approved in Europe for triple negative breast cancer Tecentriq approved in Europe for triple negative breast cancer

    So far Tecentriq’s rivals in the market have failed to match its results in TNBC, which will help it build a lead in the therapy area, which it estimated last ... Roche has a novel therapy in its late stage pipeline for TNBC, ipatasertib (RG7440), a

  • AstraZeneca buys FDA priority review voucher from Sobi AstraZeneca buys FDA priority review voucher from Sobi

    The PRV is a useful tool to have in its arsenal for this therapy area. ... Last June, Alexion used its own PRV for its rare blood disorder therapy ravulizumab, a follow-up to Soliris which is already approved in the same indication.

More from news
Approximately 0 fully matching, plus 229 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 47 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

  • Maloff Mosquito

    Therapy area: OTC Products.

  • Diagnosing the lag in neuropsychiatric treatments

    However, despite this huge unmet need, big pharma has reduced its investment in this area significantly during the past twenty years. ... Alongside the distressing impact of these disorders on patients, their carers and families, from a health economics

  • Making a difference with patient support

    The answer lies in the methodology. The specific implementation of a PSP and its key deliverables will depend on the therapy area, the drug and the audience. ... What communication channels do patients in this area prefer? Well-executed PSPs offer a

  • Good data is nothing without advocacy

    Quality and quantity of relationships within the therapy area. Willingness to engage.

  • Curb your enthusiasm (if you want to impress)

    It involves understanding your customers' unmet needs and unspoken concerns, spotting overlooked opportunities and 'hidden truths' about the brand or therapy area, and expressing those truths in a novel and arresting

More from PMHub
Approximately 2 fully matching, plus 78 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics